Particularly, the DAPA-CKD trial (Dapagliflozin in Patients with Chronic Kidney Disease) enrolled 4304 subjects with an estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 and an albumin-to-creatinine ratio (UACR) between 200 and 5000, intending to explore the occurrence of a composite primary end-point of sustained decline in the eGFR by at least 50% for end-stage kidney disease (ESKD) and death from renal or CV causes. This evidence concerns the gene ALB and chronic kidney disease.